Drugs Containing Excipient (Inactive Ingredient) SODIUM SACCHARIN

« Back to Dashboard

Branded drugs containing SODIUM SACCHARIN excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Septodont Inc	FLAVALTA	lidocaine hydrochloride and epinephrine	0362-1200	SODIUM SACCHARIN

Generic drugs containing SODIUM SACCHARIN excipient

Company	Ingredient	NDC	Excipient
Septodont Inc	lidocaine hydrochloride and epinephrine	0362-1200	SODIUM SACCHARIN
A-S Medication Solutions	acetaminophen and codeine phosphate	50090-0215	SODIUM SACCHARIN
A-S Medication Solutions	prednisolone sodium phosphate	50090-1582	SODIUM SACCHARIN
A-S Medication Solutions	lidocaine hydrochloride	50090-7040	SODIUM SACCHARIN
A-S Medication Solutions	prednisolone	50090-7115	SODIUM SACCHARIN

Sodium Saccharin Pharmaceutical Excipient Market Dynamics and Financial Trajectory

Last updated: October 21, 2026

Sodium saccharin is a mature, low-cost, high-intensity sweetening excipient used mainly in oral liquids, chewable tablets, lozenges, dental products, and selected solid-dose formulations. Its financial profile is commodity-like: demand is stable, pricing is competitive, and profitability depends more on manufacturing scale, purity control, energy costs, regulatory compliance, and supply-chain position than on intellectual property.

The pharmaceutical segment is smaller than food, beverage, and oral-care demand. Public company filings and government statistics do not report sodium saccharin revenue as a standalone category. The most defensible commercial conclusion is that pharmaceutical demand is recurring but unlikely to produce pharmaceutical-style margins or exclusivity.

What is sodium saccharin and how is it used in pharmaceuticals?

Sodium saccharin is the sodium salt of saccharin, identified by CAS Registry Number 128-44-9. Its molecular formula is C7H4NNaO3S and its molecular weight is approximately 205.17 g/mol.[1]

It is used primarily as a sweetening agent and taste-masking excipient. It has very high sweetness relative to sucrose, allowing manufacturers to use low concentrations. Typical pharmaceutical applications include:

Application	Commercial role
Oral solutions and syrups	Masks bitter or metallic active ingredients
Chewable tablets	Improves palatability without adding substantial mass
Lozenges and troches	Supports patient acceptability
Effervescent products	Provides sweetness in low-dose formulations
Dental and oral-care products	Sweetens toothpaste, mouthwash, and medicated rinses
Pediatric medicines	Helps address taste-related adherence problems
Veterinary medicines	Improves acceptance of oral dosage forms

Sodium saccharin does not materially improve tablet binding, disintegration, viscosity, or preservation. Its value is sensory rather than functional. That limits pricing power because formulators can often substitute other sweeteners or flavor systems.

What regulatory status does sodium saccharin have?

Sodium saccharin has established regulatory recognition as a sweetening ingredient, but the regulatory treatment differs by jurisdiction and product category.

In the United States, saccharin is regulated for specified uses under 21 C.F.R. § 180.37. The provision covers saccharin and its salts, including sodium saccharin, subject to conditions of use and labeling requirements.[2] Sodium saccharin is also listed in the U.S. Food and Drug Administration’s Inactive Ingredient Database for drug products.[3]

The United States Pharmacopeia-National Formulary includes a Sodium Saccharin monograph. Pharmaceutical-grade material is expected to meet identity, assay, impurity, water, and related quality requirements established by the applicable compendial standard.[4]

In the European Union, saccharin and its salts are recognized as food additives under the E-number system, with saccharin designated E954. Pharmaceutical manufacturers must also address excipient quality, acceptable daily intake, labeling, and patient-risk considerations under European Medicines Agency guidance.[5][6]

Regulatory issue	United States	European Union
Food additive status	Authorized under specified conditions	Authorized as E954 under food-additive rules
Pharmaceutical excipient status	Listed in FDA Inactive Ingredient Database	Used under medicinal-product excipient requirements
Compendial reference	USP-NF Sodium Saccharin monograph	European Pharmacopoeia standards may apply
Key compliance focus	Identity, purity, use level, labeling	Quality, excipient information, warnings, patient exposure
Approval pathway	No separate drug approval for excipient itself	No separate medicinal approval for excipient itself

Regulatory acceptance reduces formulation risk. It does not eliminate the need for supplier qualification, specification control, extractables and leachables review where relevant, or assessment of daily exposure.

What is the Orange Book status of sodium saccharin?

Sodium saccharin has no standalone Orange Book listing because it is an excipient, not an approved active pharmaceutical ingredient in the relevant sense.

The FDA Orange Book identifies approved drug products, active ingredients, dosage forms, routes of administration, patent information, and regulatory exclusivity. It does not provide a patent or exclusivity record for ordinary excipients such as sodium saccharin.[7]

As a result:

• There is no Orange Book patent expiry date for sodium saccharin.
• There is no Paragraph IV challenge directed to sodium saccharin as an excipient.
• There is no New Drug Application exclusivity attached to the excipient.
• A generic drug sponsor may use sodium saccharin if its formulation complies with applicable regulatory requirements and does not infringe patents covering the finished product.

What patents protect sodium saccharin?

No commercially relevant, enforceable composition-of-matter patent protects sodium saccharin itself. The compound has been known for more than a century and is in the public domain.

Potentially relevant rights may exist around:

• Manufacturing processes
• Crystallization and particle-size control
• Purification methods
• Low-impurity grades
• Formulation combinations
• Taste-masking systems
• Specific drug products containing sodium saccharin

These rights would generally protect a process or finished formulation rather than the basic excipient. They would not prevent competing manufacturers from producing sodium saccharin through non-infringing methods.

How strong is the sodium saccharin patent estate?

The core patent estate is weak or effectively absent. The commercial moat is operational rather than legal.

Protection category	Strength	Business implication
Composition patent	None of practical commercial relevance	Open competition
Excipient-use patent	Low	Broad substitution options
Manufacturing process patent	Potentially narrow	May affect a specific route or impurity profile
Formulation patent	Product-specific	Relevant only to a particular finished medicine
Trademark protection	Supplier-specific	Limited protection for commodity material
Trade secrets	Moderate	May protect yield, purification, and consistency

Patent barriers therefore have little effect on the raw-material market. A supplier’s ability to maintain validated quality, continuity of supply, and regulatory documentation is more important than patent ownership.

How large is the pharmaceutical sodium saccharin market?

A standalone, audited global market size for pharmaceutical-grade sodium saccharin is not publicly reported. Market research reports typically combine food, beverage, oral-care, animal-health, and pharmaceutical uses under broader saccharin or high-intensity sweetener categories.

The pharmaceutical segment is structurally smaller than the food and oral-care segments because:

1. Drug formulations use low quantities.
2. Many products do not require an intense sweetener.
3. Alternative sweeteners and flavor systems are available.
4. Sodium saccharin is often selected for cost and potency rather than unique therapeutic performance.
5. Finished-dose demand follows prescription, over-the-counter, pediatric, dental, and veterinary product volumes.

The addressable pharmaceutical value chain is therefore better measured by recurring formulation demand than by direct excipient revenue. A single high-volume syrup or chewable product can generate steady demand, but the raw-material value per dose remains low.

What drives demand for pharmaceutical sodium saccharin?

Demand is tied to dosage-form and patient-acceptance trends rather than to a single therapeutic class.

Oral liquid growth

Sodium saccharin is used in pediatric and geriatric oral liquids where bitterness can reduce adherence. Demand rises when manufacturers launch or reformulate liquid products, particularly for antibiotics, antipyretics, antihistamines, gastrointestinal medicines, and vitamins.

Chewable and orally disintegrating products

Chewable tablets, orally disintegrating tablets, lozenges, and sublingual products require taste management. Sodium saccharin can be combined with flavors, polyols, sucralose, aspartame, acesulfame potassium, or other sweeteners.

Dental and oral-care products

Dental products represent a large and stable use case. Sodium saccharin is compatible with many toothpaste and mouthwash systems and does not promote dental caries in the same way as fermentable sugars.

Cost pressure

Sodium saccharin remains attractive when a formulation requires high sweetness at a low use level. Manufacturers can reduce excipient cost while retaining a familiar ingredient with an established regulatory history.

Reformulation pressure

Demand can weaken when manufacturers seek sugar-free, low-sodium, clean-label, natural, or premium positioning. Some products may move toward stevia, sucralose, acesulfame potassium, monk fruit, or flavor-only systems.

How does sodium saccharin compare with competing sweeteners?

Sweetener	Relative commercial position	Main advantages	Main limitations
Sodium saccharin	Low-cost mature excipient	High potency, low use level, established supply	Aftertaste, legacy consumer perception
Sucralose	Premium synthetic alternative	Strong taste profile, broad use	Higher cost
Acesulfame potassium	Direct synthetic competitor	Stable, often blended with other sweeteners	Can have bitter notes
Aspartame	Established oral sweetener	Good taste in selected systems	Stability and phenylalanine labeling issues
Stevia glycosides	Natural-positioned alternative	Consumer preference for plant-derived ingredients	Aftertaste, formulation complexity, higher cost
Sorbitol and xylitol	Bulk sweeteners	Mouthfeel and body	Higher use levels, gastrointestinal limits
Mannitol	Bulk sweetener and filler	Cooling effect, tablet utility	Cost and processing considerations

Sodium saccharin’s strongest competitive advantage is cost per unit of sweetness. Its weakest point is taste perception, especially in formulations where a lingering or metallic note is difficult to mask.

What are the manufacturing and supply-chain barriers?

Sodium saccharin is a synthetic chemical with mature manufacturing technology. Entry barriers are lower than for active pharmaceutical ingredients, but pharmaceutical-grade supply still requires technical capability.

Key barriers include:

• Control of organic and inorganic impurities
• Consistent assay and moisture levels
• Particle-size control
• Batch-to-batch taste consistency
• GMP-compatible documentation
• Traceability of raw materials
• Control of residual solvents and related substances
• Reliable packaging and moisture protection
• Customer qualification and audit readiness
• Compliance with food, chemical, and pharmaceutical rules in destination markets

Manufacturing economics depend on precursor costs, sulfur and nitrogen chemistry, energy, wastewater treatment, labor, packaging, and freight. China has historically been an important source of saccharin and related sweetener production. Buyers therefore assess geographic concentration, export controls, environmental enforcement, port disruption, and tariff exposure.

Pharmaceutical buyers are less likely than food buyers to switch suppliers solely on price. A supplier change can require quality audits, documentation review, stability assessment, and regulatory variation analysis. That creates some customer stickiness even when the underlying chemical is interchangeable.

What is the financial trajectory for sodium saccharin suppliers?

The financial trajectory is best characterized as stable volume, low-to-moderate pricing power, and margin sensitivity.

Financial factor	Expected effect
Pharmaceutical demand	Recurring but modest growth
Food and beverage demand	Larger volume base, higher exposure to consumer trends
Raw-material costs	Direct impact on gross margin
Energy and environmental costs	Important for production economics
Freight and tariffs	Can change regional competitiveness
Supplier qualification	Supports retention after approval
Product substitution	Caps long-term pricing power
Premium pharmaceutical grade	Supports modest price premium
Patent exclusivity	Minimal effect

A practical financial model is:

Revenue = qualified volume × realized price

Gross profit = revenue - raw materials - conversion costs - quality costs - freight and compliance costs

For sodium saccharin, realized price is constrained by multiple qualified suppliers and substitute sweeteners. Margin expansion is more likely to come from manufacturing efficiency, higher plant utilization, premium documentation, and regional supply advantages than from price increases.

2024-2028 directional outlook

Period	Market condition	Financial implication
2024-2025	Stable pharmaceutical and oral-care demand; continued supplier competition	Limited pricing power
2025-2026	Ongoing formulation demand for liquids and chewables; freight and compliance remain variable	Volume-led revenue growth
2026-2028	Mature market with substitution pressure and regional sourcing initiatives	Low-single-digit structural growth is more plausible than rapid expansion

The principal downside risks are substitution by sucralose or stevia-based systems, supplier consolidation, environmental compliance costs, and reduced use of artificial sweeteners in consumer-facing products. The principal upside drivers are growth in pediatric oral liquids, generic reformulations, oral-care products, and contract manufacturing.

Which companies are challenging sodium saccharin exclusivity?

No meaningful exclusivity challenge exists because sodium saccharin is not protected by an active pharmaceutical patent or regulatory exclusivity period.

Competition occurs at the supplier level. Buyers typically evaluate:

• Product purity and compendial compliance
• Manufacturing location
• Audit history
• Capacity and lead time
• Regulatory support
• Packaging configuration
• Price and payment terms
• Ability to maintain multi-year supply

This is a procurement competition rather than a patent litigation market.

What patent litigation and settlement activity affects sodium saccharin?

There is no major Orange Book litigation, Paragraph IV litigation, biosimilar litigation, or settlement structure associated with sodium saccharin as a pharmaceutical excipient.

Any dispute is more likely to concern:

• A finished drug’s taste-masking formulation
• A proprietary granulation or coating process
• A supplier’s manufacturing process
• Product quality or specification compliance
• Contract supply and change-control obligations

The absence of core patent protection means litigation risk for the excipient itself is low. Finished-product sponsors must still review formulation patents before launching a product that uses sodium saccharin.

What generic launch risks exist when a drug uses sodium saccharin?

Use of sodium saccharin does not create a generic-entry barrier. A generic sponsor can generally use the same excipient or a functional alternative, subject to formulation equivalence, quality, labeling, and applicable regulatory requirements.

The relevant risks are product-specific:

• A listed drug may have a patented taste-masking system.
• A controlled-release formulation may claim a particular excipient combination.
• A pediatric formulation may have method-of-use or dosage-form patents.
• The innovator may rely on trade secrets involving flavor balance or processing.
• The generic may need comparative studies if the excipient affects bioavailability or performance.

Sodium saccharin itself is not the source of exclusivity.

How does sodium saccharin compare with pharmaceutical excipients that have stronger IP?

Sodium saccharin differs sharply from specialty excipients such as lipid nanoparticles, engineered polymers, proprietary solubilizers, and controlled-release systems.

Attribute	Sodium saccharin	Specialty excipient
Core patent protection	Minimal	Often significant
Supplier switching	Relatively feasible	Often difficult
Qualification burden	Moderate	High
Price per kilogram	Low	Often materially higher
Formulation differentiation	Limited	Potentially substantial
Regulatory dependence	Established	May require extensive justification
Margin potential	Commodity-like	Specialty-like

Investors and licensing teams should not assign a specialty-excipient valuation multiple to sodium saccharin without evidence of a differentiated grade, proprietary process, or captive formulation application.

Key Takeaways

• Sodium saccharin is a mature pharmaceutical sweetening excipient with recurring demand.
• Its main applications are oral liquids, chewables, lozenges, dental products, and selected veterinary medicines.
• The United States recognizes saccharin and its salts under specified conditions, and sodium saccharin appears in the FDA Inactive Ingredient Database.
• Sodium saccharin has no standalone Orange Book listing, Paragraph IV pathway, or drug exclusivity period.
• The core compound is public domain. Commercial protection depends on manufacturing quality, customer qualification, and supply reliability.
• Pharmaceutical demand is smaller than food, beverage, and oral-care demand.
• Financial performance is driven by volume, plant utilization, raw-material costs, environmental compliance, and logistics.
• Generic entry risk created by sodium saccharin is low. Relevant patent risk usually comes from the finished formulation.
• The market outlook is stable rather than high growth, with modest volume expansion and persistent pricing pressure.
• Supplier differentiation is operational, not patent-based.

FAQs

Is sodium saccharin safe as a pharmaceutical excipient?

Sodium saccharin is an established sweetening ingredient with regulatory limits and use conditions. Product developers must assess total exposure, patient population, labeling, and applicable jurisdictional requirements.

Can sodium saccharin be used in pediatric medicines?

Yes. It is used in pediatric oral liquids and chewable products to improve palatability. The formulation must address total daily exposure, taste profile, age-specific labeling, and applicable excipient requirements.

Does sodium saccharin require a Drug Master File?

A Drug Master File is not automatically required for every sodium saccharin supplier. The need depends on the drug sponsor’s regulatory strategy, the level of confidential manufacturing information, customer requirements, and the applicable filing jurisdiction.

Is pharmaceutical-grade sodium saccharin more expensive than food-grade material?

It can command a premium because of compendial testing, documentation, audit requirements, packaging, traceability, and change-control obligations. The premium is generally limited by the availability of alternative suppliers.

Can a pharmaceutical company replace sodium saccharin without a new patent review?

A formulation change can require regulatory and quality review even when no patent issue exists. The company must assess bioequivalence, taste, stability, labeling, manufacturing performance, and any patents covering the finished dosage form.

References

1. National Center for Biotechnology Information. (n.d.). PubChem compound summary for sodium saccharin. PubChem.
2. U.S. Food and Drug Administration. (2024). 21 C.F.R. § 180.37: Saccharin and its salts. Electronic Code of Federal Regulations.
3. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database.
4. United States Pharmacopeial Convention. (2024). Sodium saccharin monograph. United States Pharmacopeia-National Formulary.
5. European Commission. (2024). EU food additives database: E954 Saccharins.
6. European Medicines Agency. (2017). Guideline on the quality of medicines for paediatric use.
7. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.